Prednisone Dosing for Chronic Sinusitis in Patients with Controlled Diabetes Mellitus

Recommended Dosing Regimen

For patients with chronic sinusitis and controlled diabetes mellitus, the American Academy of Otolaryngology recommends a short course of oral prednisone at 25 mg daily for 2 weeks, followed by intranasal corticosteroids for maintenance therapy 1, 2
For chronic sinusitis with nasal polyps, prednisone 25 mg daily for 2 weeks is the optimal dose that balances efficacy and minimizing adverse effects in patients with controlled diabetes 1, 2
Following oral prednisone, transition to intranasal corticosteroids (e.g., fluticasone propionate nasal spray) for long-term maintenance 1, 2

Short courses of oral corticosteroids significantly improve nasal symptoms, nasal airflow, and polyp size at 2 weeks compared to placebo, with a moderate strength of evidence 1
The combination of oral corticosteroids followed by intranasal corticosteroids provides greater improvement in symptoms, nasal polyp scores, and quality of life compared to intranasal corticosteroids alone, based on high-quality evidence 1, 2
Improvements in sense of smell, nasal airflow, and polyp size can persist for up to 12 weeks when followed by intranasal corticosteroid maintenance, with a moderate strength of evidence 1

Patients with diabetes require careful monitoring of blood glucose levels during and after prednisone therapy, as recommended by the American Diabetes Association 3
For patients on oral hypoglycemic agents, dose adjustments may be necessary during prednisone treatment, according to the American Diabetes Association 3
Lower doses (25 mg rather than 40-60 mg) help minimize glycemic fluctuations while maintaining efficacy for sinusitis, based on evidence from the European Association for the Study of Diabetes 4, 3

Check blood glucose levels daily during prednisone treatment in diabetic patients, as recommended by the American Diabetes Association 3
Monitor for signs of hyperglycemia (increased thirst, frequent urination, fatigue) in diabetic patients, according to the American Diabetes Association 3
Consider temporary adjustments to diabetes medications during prednisone treatment, based on guidelines from the American Diabetes Association 3
The risk of adrenal suppression is minimal with a 2-week course but should be considered if the patient has been on previous corticosteroid therapy, with a low strength of evidence 4, 5

Patients with diabetes have an increased risk of transient hyperglycemia during treatment, based on evidence from the American Diabetes Association 4, 3
The risk of significant adverse events is low with short courses (2 weeks or less) but increases with longer duration of therapy, with a moderate strength of evidence 4

For patients with severe diabetes concerns, consider a shorter course (7 days) or lower dose (15-20 mg) with closer glucose monitoring, as recommended by the American Diabetes Association 3

Evaluate response after completing the 2-week oral prednisone course, based on guidelines from the American Academy of Otolaryngology 1
Continue intranasal corticosteroids for at least 10-12 weeks after oral prednisone to maintain improvements, with a moderate strength of evidence 1, 2
Limit oral corticosteroid courses to 1-2 per year to minimize systemic adverse effects, especially in diabetic patients, based on recommendations from the European League Against Rheumatism 4, 3